GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of genuine question about TRIUMPH that I am slightly embarrassed to ask — 48 comments in the full submission. View in context.
3.2k
c/trialwatch·submitted 2 years ago by u/joaquin_trevino

genuine question about TRIUMPH that I am slightly embarrassed to ask

Trial Databranch of 9 comments

Trying to get a straight answer on this: genuine question about TRIUMPH that I am slightly embarrassed to ask. Why comparing across trials almost never works, with the specific failure modes. Different populations: an obesity programme and a diabetes programme enrol different people with different baseline…

Read the full submission and all 48 comments →

This branch

9 comments, started 2 years ago
u/anders_karlsen387 points·2 years ago

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

replysharereportpermalink
u/cold_chromatogram31120 points·2 years ago

What did the confidence interval look like?

replysharereportpermalink
u/tove_ogunleye56 points·2 years ago

the confidence interval is the finding, the point estimate is the headline

replysharereportpermalink
u/joaquin_trevinoOP-8 points·2 years ago

the confidence interval is the finding, the point estimate is the headline

Agreed. And the interval, not the point estimate, is what the trial actually established.

replysharereportpermalink
u/joaquin_trevinoOP0 points·2 years ago

Correcting myself upthread: I gave the completer figure and labelled it intention-to-treat.

replysharereportpermalink
u/whois_wanda36 points·2 years ago

a mean is not a promise

replysharereportpermalink
u/renal_outcomes_rnephro-curious8 points·2 years ago

trial populations get support that nobody on this board gets

replysharereportpermalink
u/ferran_dahlberg202 points·2 years ago

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.